Drug · DIN 02570270
SHINGRIX
HERPES ZOSTER VACCINE (NON-LIVE RECOMBINANT, AS01B ADJUVANTED). READY-TO-USE SINGLE-DOSE PREFILLED SYRINGE
Authorized, not yet reported as sold
Authorized for sale in Canada; the company has not yet told Health Canada that it is on the market.
Status Approved since July 23, 2026.
- Drug Identification Number (DIN)
- 02570270
- Company (DIN owner)
- Glaxosmithkline IncMississauga, Ontario, Canada
- Schedule
- Schedule d
- Dosage form
- Suspension
- Route
- Intramuscular
- Therapeutic class (ATC)
- Varicella zoster vaccines J07BK
- Class
- Human
- Record last updated
- September 4, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| VARICELLA-ZOSTER VIRUS GLYCOPROTEIN E ANTIGEN | 50 MCG | 0.5 ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- July 23, 2026: NOC 37969Supplement to a New Drug Submission (SNDS) · New formulation and presentation
Other DINs named SHINGRIX
- DIN 02468425 · Marketed